ABSTRACT This study was designed to determine whether resistance to the airway effects of the beta-agonist, salbutamol, would develop in three groups of subjects while taking large doses of inhaled salbutamol. Six normal non-atopic, six atopic non-asthmatic, and eight atopic asthmatic subjects were studied by an identical technique. The development of resistance was assessed from salbutamol dose-response studies in which the airway response was measured as specific airway conductance (sGaw). Further evidence was sought in the atopic and asthmatic subjects by measuring the airway response to a standard histamine inhalation challenge and the protective effect of 100 f4g salbutamol on this challenge, and by six-hourly peak flow recordings. Subjects were assessed before and during four weeks in which they took inhaled salbutamol regularly in doses increasing to 500 /g qid in week 4. Normal subjects showed a progressive reduction in the bronchodilator (sGaw) response to salbutamol during the four weeks, indicating the progressive development of resistance. The atopic subjects, both asthmatic and non-asthmatic, showed no reduction in the response to salbutamol during the four weeks, nor any change in the response to histamine challenge or in regular peak flow readings. These results demonstrate that asthmatic patients do not develop bronchial beta-adrenoceptor resistance easily and suggests that they and atopic non-asthmatic subjects are less susceptible to its development than normal subjects.
When the sales of isoprenaline aerosols were found to have increased and decreased in parallel with the rise and fall in asthma deaths in the United Kingdom in the 1960s, a causative association was suggested' and though supported by circumstantial evidence was never proved. 23 Explanations for a possible association included the provocation of cardiac arrythmias by isoprenaline3 or alternatively the development of tolerance or resistance to this and other beta-agonists so that patients would then fail to respond to either endogenous or exogenous catecholamines during an acute episode of asthma.4 This possibility was supported by two retrospective studies of patients taking excessive amounts of inhaled isoprenaline who, when tested, showed little bronchodilator response to inhaled isoprenaline.
Once isoprenaline inhaler usage was reduced or discontinued their bronchodilator response returned.5 6 The development of beta-adrenoceptor resistance after beta-agonist treatment has been demonstrated for the tremor,7 metabolic,8-10 heart rate,411 and white cell cyclic-AMP12 14 responses to beta-agonists in both normal subjects and patients with asthma. The important question of whether patients with asthma develop bronchial betaadrenoceptor resistance as a result of large or even moderate doses of beta-agonists has been investigated in more than 30 studies in the last decade. In the majority, drug-induced bronchial resistance could not be demonstrated,715 18 and when it did occur the changes were usually small. 10 19-21 This is in contrast to the only study in normal subjects where bronchial beta-adrenoceptor resistance developed progressively over four weeks as subjects took increasing doses of inhaled salbutamol.22 This apparent difference between normal and asthmatic subjects may be a true difference, or may be the result of differences in technique and problems inherent in studying patients with asthma.
This study was therefore designed to compare three groups of subjects using an identical technique Table 1 Details of subjects in the three groups   Normal   Atopy  Asthma   Sex  Male  5  4  7  Female  1  2  1  Age (years)  Mean  31  32  29  Range  18-57  23-50  22-53  % predicted  FEV1  117  113  91  SEM   7-4 3-9 8-0 -normal subjects, atopic non-asthmatic subjects, and atopic asthmatic patients. Subjects were studied before and during four weeks in which they inhaled increasing doses of salbutamol.
Methods

SUB JECTS
All subjects agreed to participate after a full explanation of the protocol which was agreed by the Southampton Ethical Committee. Details of the six normal subjects, six atopic non-asthmatic subjects, and eight asthmatic subjects who participated are shown in table 1; all were non-smokers. Normal subjects were healthy, had no respiratory symptoms, and no personal or family history of asthma or allergy. All had negative skin prick tests to five common allergens and less than 10% change in FEV1 after 100 jug inhaled salbutamol.
The atopic non-asthmatic subjects gave a typical history of hay fever and had at least two positive skin prick tests to five common allergens, one being mixed grass pollen. They showed less than 10% change in PEFR during recordings four times daily for four days and after 100 jug inhaled salbutamol, and less than 10% fall in FEV1 after six minutes' exercise on a bicycle ergometer at 100 watts and after a two-minute inhalation of 0.5% histamine. They were studied in winter when asymptomatic.
The asthmatic subjects gave a history of intermittent wheezing attacks for at least five years, had positive skin prick tests to at least two in the control study (p = 0 08).
HISTAMINE CHALLENGE STUDIES
Control baseline values of sGaw and FEV1 were lower in the asthmatic than the atopic subjects. Neither group showed any significant change in baseline sGaw or FEV1 between control period and week 4 (table 2), nor any difference in the sGaw or FEV1 response to histamine or in the protection afforded by salbutamol against histamine challenge (fig 3) .
PEAK EXPIRATORY FLOW RATES
Mean values for PEFR in the control studies were 585 ± 9 7 and 494 ± 9-8 1/min respectively for the atopic, non-asthmatic, and asthmatic groups (102 and 83 % predicted). There was no significant change in the mean values during week 4 (593 ± 9 8 and 519 ± 9-2 I/min) nor any consistent change in individual peak expiratory flow patterns (fig 4) .
Discussion
This is the first prospective study to compare airway responsiveness to a beta-agonist in normal and asthmatic subjects before and during treatment with large doses of inhaled salbutamol using the same technique. By choosing patients with mild and relatively stable asthma the problem of fluctuating airway calibre was reduced. The results suggest that normal subjects develop resistance after doses of inhaled salbutamol which do not cause resistance in asthmatic subjects. Baseline sGaw was lower in the asthmatic patients in the control study but the percentage increase in sGaw in response to salbutamol was similar in both groups (60 and 65%). The atopic subjects had a smaller response to salbutamol (30%), possibly because of their higher baseline sGaw, though this did not differ significantly from sGaw in the normal subjects.
After regular inhaled salbutamol the response of the normal and asthmatic subjects differed, with normal subjects developing a progressive fall in their airway response to salbutamol, while the asthmatic subjects clearly maintained their response. The extent and time-course of beta-adrenoceptor resistance in the normal subjects is very similar to that demonstrated in the only previous airway study of normal subjects. 22 The atopic non-asthmatic subjects responded like the asthmatic patients, maintaining their airway responsiveness to salbutamol. The absence of any detectable resistance by week 4 in the salbutamol dose-response studies in these patients was further supported by the lack of any consistent change in the airway response to inhaled histamine or the protection afforded by salbutamol against a histamine challenge. Peak expiratory flow rates in both atopic and asthmatic subjects also showed no change in either mean values or diurnal pattern during the study. We have no way of ensuring that all subjects took regular salbutamol as prescribed, but all were considered reliable, all used a similar number of inhalers, and the findings were consistent within each group. The findings also fit with the clinical impression that patients with asthma rarely develop bronchial resistance to beta-agonists when inhaling amounts close to or above the recommended maximum dose. These results, therefore, suggest a true difference between normal subjects and asthmatic subjects, with atopic non-asthmatic subjects behaving like asthmatic subjects in this respect. The difference is probably a relative one since the studies of Van Metre5 and Reisman6 strongly suggest that bronchial beta-adrenoceptor resistance did develop in patients taking very large doses of beta-agonistsup to one inhaler a day.
The results in the asthmatic patients agree with most previous prospective studies in asthma in which comparable doses of beta-agonists have been used. These have usually been unable to demonstrate the development of bronchial beta-adrenoceptor resistance;7 15-18 in contrast to studies on non-bronchial beta-adrenoceptor responses (tremor, heart rate, lymphocyte and leucocyte cyclic-AMP, and intermediary metabolites) where resistance has frequently developed.7 1014 Doses of beta-adrenoceptor agonists which result in impairment of tremor, lymphocyte cyclic-AMP, or metabolic responses in asthmatic patients may not impair airway responses,7 12 24 even when given by inhalation.24 This suggests that tissues vary in the ease with which they develop resistance, with bronchial tissue being considerably less susceptible than other tissues in asthmatic patients.
The reduction in baseline FEV1 after four weeks' salbutamol treatment in the atopic and asthmatic subjects was unexpected and not associated with a significant reduction in sGaw. The changes may be transient since they were not found before histamine challenge in week 4, nor was there any concurrent fall in PEFR or clinical deterioration. These results could be a chance finding, although a similar fall in PEFR and FEV1 has been reported previously after regular adrenergic therapy.2125 Since the changes affected FEV1 rather than sGaw they may reflect narrowing of small airways. A possible explanation would be increased bronchial mucus production since this has been demonstrated in animals and man after treatment with beta-adrenoceptor agonists. 26 27 Alternatively, sudden withdrawal of large doses of beta-agonists may upset the autonomic control of mast cells,28 allowing a transient increase in mediator release.
The reason why normal and asthmatic subjects differ in their response to large doses of beta-agonists is not clear. Although asthmatic patients in this study showed no change in airway responsiveness to salbutamol after four weeks' regular salbutamol, the plasma cyclic-AMP response to intravenous salbutamol in the same subjects was reduced. 24 If plasma cyclic-AMP levels reflect intracellular cyclic-AMP levels in bronchial smooth muscle, failure to develop bronchial beta-adrenoceptor resistance suggests that there may be a protective mechanism independent of the beta-adrenoceptor. For example, increased intracellular steroid levels might induce a cyclic-AMP dependent protein kinase to augment the effect of intracellular cyclic-AMP.29 Alternatively, our findings may be the result of changes in the beta-adrenoceptor since plasma cyclic-AMP levels may not reflect concentrations of cyclic-AMP in bronchial smooth muscle, particularly in view of the differing susceptibilities of different tissues to develop resistance.
Recent beta-adrenoceptor radioligand binding studies have suggested that asthma may be associated with a reduced number of beta-adrenoceptors,30 or a relative increase in the alpha to beta-adrenoceptor ratio.31 32 Most of these changes are likely to be caused by previous treatment with beta-agonists since patients with asthma on no treatment have a normal number of leucocyte beta-adrenoceptor binding sites,33 and excess agonist, both in vitro34 and in ViVo35 in normal subjects cause a reduction in leucocyte beta-adrenoceptor numbers. The number of beta-adrenoceptor radioligand binding sites does not necessarily reflect functional activity. An 850% reduction in leucocyte dihydroalprenolol binding sites was found in asthmatic subjects after moderate doses of oral terbutaline for only six days35 in marked contrast to the complete lack of any functional impairment in airway beta-adrenoceptor responsiveness in both our study and in previous studies of oral terbutaline.7 Also, the increased alpha/beta adrenoceptor ratio in sensitised guinea-pig lung was not associated with any change in the adenylate cyclase response to isoprenaline.32 The 
